Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Analysts at Chardan Capital

Chardan Capital initiated coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report released on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $60.00 price target on the stock.

Other research analysts also recently issued reports about the stock. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Jones Trading reiterated a “hold” rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Piper Sandler reissued an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $56.50.

Monopar Therapeutics Trading Down 4.1%

MNPR stock opened at $31.92 on Monday. The firm has a 50 day moving average of $36.96 and a 200-day moving average of $34.60. Monopar Therapeutics has a 12 month low of $1.72 and a 12 month high of $54.30. The firm has a market capitalization of $195.35 million, a P/E ratio of -9.17 and a beta of 0.99.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.27. Sell-side analysts predict that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Activity

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the sale, the insider now owns 822,255 shares in the company, valued at $28,778,925. This trade represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new position in Monopar Therapeutics in the fourth quarter worth about $45,000. Geode Capital Management LLC boosted its position in Monopar Therapeutics by 174.4% in the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after buying an additional 24,530 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $2,861,000. Adage Capital Partners GP L.L.C. purchased a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $13,182,000. Finally, RA Capital Management L.P. acquired a new position in Monopar Therapeutics in the fourth quarter valued at approximately $11,247,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.